August 25, 2023.
Atmo Biosciences is one of only five businesses accepted into the market-leading ANDHealth+ commercialization program, which helps digital health companies to scale their products nationally and internationally.
August 25, 2023.
Atmo Biosciences is one of only five businesses accepted into the market-leading ANDHealth+ commercialization program, which helps digital health companies to scale their products nationally and internationally.
August 10, 2023.
Atmo Biosciences today announced it has commenced a pivotal clinical study to assess the use of the Atmo Gas Capsule to measure gastrointestinal transit time in patients with suspected motility disorders.
The study involves simultaneous ingestion of the Atmo Gas Capsule and predicate device SmartPill to demonstrate the ability of Atmo’s gas-sensing capsule to assess whole and regional gut transit. Clinicians evaluate regional gut transit to help diagnose motility disorders such as gastroparesis (delayed emptying from the stomach), and slow transit constipation (slow transit through the colon).
6 July, 2023.
A Monash University clinical study published in the journal Alimentary Pharmacology & Therapeutics1 has found that Atmo Biosciences’ gas-sensing capsule can be used to provide insights into localization of colonic fermentation.
17 May, 2023.
Preliminary results from a University of Queensland (UQ) study to assess how the Atmo Gas Capsule compares to established SIBO (small intestinal bacterial overgrowth) diagnostic methods suggest a good correlation with duodenal aspirate and higher accuracy than a breath test.
Dr Ayesha Shah, a senior lecturer at the UQ School of Medicine, presented data from the study, led by Professor Gerald Holtmann, also from UQ, and Professor Uday Chand Ghoshal of Sanjay Gandhi Postgraduate Institute of Medical Sciences, India, in a presentation at Digestive Disease Week (DDW), held May 6-9 in Chicago.
15 May, 2023.
A Western Sydney University (WSU) and Monash University comparative study has validated the Atmo Gas Capsule relative to the SmartPill when measuring gastric emptying time and colonic transit time in patients with gastroparesis and chronic constipation.
Dr Jerry Zhou, lecturer and clinical researcher at WSU School of Medicine, presented findings from the study in a poster presentation at Digestive Disease Week (DDW), held May 6-9 in Chicago.
17 April, 2023.
Atmo Biosciences is strengthening its U.S. focus with the appointment of experienced medical device executive Chris Bertrand to the Atmo Board and establishment of a San Diego, California office.
Atmo Biosciences has raised A$8 million in a fully subscribed Series B funding round.
The raise was led by Japanese multinational company Otsuka Pharmaceutical, an existing strategic shareholder that took up more than its pro rata entitlement.